SCHEDULE 13G/A: Leviticus Partners LP and AMH Equity LLC Disclose 8.1% Stake in Harvard Bioscience Inc.

Leviticus Partners LP and AMH Equity LLC have filed an amended Schedule 13G, reporting a beneficial ownership of 8.1% of Harvard Bioscience Inc.'s common stock.

Summary

• Leviticus Partners LP and AMH Equity LLC, managed by Adam M Hutt, collectively beneficially own 3,600,000 shares of Harvard Bioscience Inc. common stock.
• This ownership represents 8.1% of the total outstanding common stock of Harvard Bioscience Inc.
• Leviticus Partners LP holds sole voting and sole dispositive power over all 3,600,000 shares.
• The filing is an Amendment No. 3 to a previously filed Schedule 13G.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a significant institutional stake in the company, which can be viewed as a vote of confidence, without suggesting any immediate activist intentions or negative implications.

Positives

• The disclosure of a significant 8.1% stake by institutional investors like Leviticus Partners LP and AMH Equity LLC may signal confidence in Harvard Bioscience Inc.'s prospects.
• The certification that shares are held in the ordinary course of business and not for control purposes suggests a passive investment, potentially reducing concerns about immediate activist intervention.

Risks

• The document itself does not detail specific risks related to Harvard Bioscience Inc.'s operations or financial health, as it is a beneficial ownership disclosure.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Harvard Bioscience Inc.'s future outlook.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a routine disclosure of a significant ownership stake by institutional investors in Harvard Bioscience Inc., a company operating in the life sciences tools and technologies sector. It reflects an investor's position rather than broader industry trends.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially signaling confidence in the company's prospects and stability, given the passive nature of the investment.

Next Steps

• The reporting persons will file further amendments to this Schedule 13G if there are material changes to their beneficial ownership of Harvard Bioscience Inc. common stock.

Key Dates

Keywords

Harvard Bioscience, Common Stock, Schedule 13G, Beneficial Ownership, Institutional Investor, Equity Stake, SEC Filing, Leviticus Partners LP, AMH Equity LLC, Adam M Hutt